Infection with Helicobacter pylori Is Associated with Protection against Tuberculosis

Abstract

Background

Helicobacter pylori, a lifelong and typically asymptomatic infection of the stomach, profoundly alters gastric immune responses, and may benefit the host in protection against other pathogens. We explored the hypothesis that H. pylori contributes to the control of infection with Mycobacterium tuberculosis.

Methodology/Principal Findings

We first examined M. tuberculosis-specific IFN-γ and H. pylori antibody responses in 339 healthy Northern Californians undergoing routine tuberculin skin testing. Of 97 subjects (29%) meeting criteria for latent tuberculosis (TB) infection (LTBI), 45 (46%) were H. pylori seropositive. Subjects with LTBI who were H. pylori-seropositive had 1.5-fold higher TB antigen-induced IFN-γ responses (p = 0.04, ANOVA), and a more Th-1 like cytokine profile in peripheral blood mononuclear cells, compared to those who were H. pylori seronegative. To explore an association between H. pylori infection and clinical outcome of TB exposure, we evaluated H. pylori seroprevalence in baseline samples from two high risk TB case-contact cohorts, and from cynomolgus macaques experimentally challenged with M. tuberculosis. Compared to 513 household contacts who did not progress to active disease during a median 24 months follow-up, 120 prevalent TB cases were significantly less likely to be H. pylori infected (AOR: 0.55, 95% CI 0.0.36–0.83, p = 0.005), though seroprevalence was not significantly different from non-progressors in 37 incident TB cases (AOR: 1.35 [95% CI 0.63–2.9] p = 0.44). Cynomolgus macaques with natural H. pylori infection were significantly less likely to progress to TB 6 to 8 months after M. tuberculosis challenge (RR: 0.31 [95% CI 0.12–0.80], p = 0.04).

Conclusions/Significance

H. pylori infection may induce bystander effects that modify the risk of active TB in humans and non-human primates. That immunity to TB may be enhanced by exposure to other microbial agents may have important implications for vaccine development and disease control.

About the Authors:

Sharon Perry

* E-mail: [email protected]

Affiliation: Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, California, United States of America

Bouke C. de Jong

Affiliation: Medical Research Council Laboratories, Fajara, The Gambia

Jay V. Solnick

Affiliation: Departments of Medicine and Microbiology and Immunology, Center for Comparative Medicine, University of California Davis School of Medicine, Davis, California, United States of America

Maria de la Luz Sanchez

Affiliation: Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, California, United States of America

Shufang Yang

Affiliation: Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, California, United States of America

Philana Ling Lin

Affiliation: Department of Pediatrics, University of Pittsburgh School of Medicine, Children's Hospital, Pittsburgh, Pennsylvania, United States of America

Lori M. Hansen

Affiliation: Departments of Medicine and Microbiology and Immunology, Center for Comparative Medicine, University of California Davis School of Medicine, Davis, California, United States of America

Najeeha Talat

Affiliation: Department of Pathology and Microbiology, Aga Khan University, Karachi, Pakistan

Philip C. Hill

Affiliation: Medical Research Council Laboratories, Fajara, The Gambia

Rabia Hussain

Affiliation: Department of Pathology and Microbiology, Aga Khan University, Karachi, Pakistan

Richard A. Adegbola

Affiliation: Medical Research Council Laboratories, Fajara, The Gambia

JoAnne Flynn

Affiliation: Departments of Microbiology and Molecular Genetics and Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America

Don Canfield

Affiliation: Departments of Medicine and Microbiology and Immunology, Center for Comparative Medicine, University of California Davis School of Medicine, Davis, California, United States of America

Julie Parsonnet

Affiliation: Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, California, United States of America

Introduction

The microbes that colonize the human host are diverse and demonstrate geographic and temporal variability. This variability is exemplified by H. pylori infection, a gastric mucosal pathogen that comprises part of the “normal flora” in much of the developing world, but has receded over time in higher socioeconomic regions of the world. H. pylori has been colonizing humans for at least 50,000 years [1]. Why its prevalence varies so dramatically based on socioeconomic status is not known but may relate to antimicrobial use, improved household and environmental sanitation, and decreased crowding. Another hypothesis, however, is that H. pylori infection provides a survival benefit against challenges present disproportionately in poorer geographic regions. By boosting mucosal and systemic immunity, the organism may limit the consequences of other infectious exposures [2], [3] and selectively promote survival of H. pylori infected hosts.

One third of the world's population is latently infected with the intracellular pathogen M. tuberculosis [4]. Following exposure, the organism elicits an IFN-γ-driven, cellular immune response, causing infected macrophages to be sequestered within organized lung granulomas [5], [6]. In approximately 90% of humans, the host immune response controls but does not eliminate the infection, preventing progression to active disease throughout the host's lifespan [7]. Those infected with M. tuberculosis but with no symptoms of disease are referred to as latently infected. Although risk of active tuberculosis is significantly elevated in immunocompromised hosts (e.g., those with HIV infection [8] or treated with immunosuppressants [9]), the great majority of individuals who develop active TB do so in the absence of known immunocompromise. The nature of protective immunity remains unknown.

M. tuberculosis and H. pylori are the most prevalent bacterial pathogens worldwide. In much of the world's population, these obligate human infections coexist throughout most of the life span, continuously interacting with the host immune system without causing disease. Almost nothing is known about the crosstalk of these infections and whether one infection affects the clinical manifestations of the other. The few studies examining an epidemiologic linkage between H. pylori and tuberculosis have yielded conflicting results [10], [11], [12]. While conducting a study of TB diagnostics in a population that had been tested for H. pylori, we fortuitously identified differences in interferon gamma (IFN-γ) and other cytokine responses to M. tuberculosis antigens in H. pylori-infected and uninfected hosts. To explore this relationship further, we compared rates of H. pylori seropositivity in blood samples from TB cases and household contacts recruited from TB case-contact studies carried out in The Gambia [13] and Karachi, Pakistan [14]. We also compared outcome of M. tuberculosis challenge [15] in macaques with and without naturally-acquired H. pylori infection. Our results support further investigations into the contribution of H. pylori infection to the protective immune response to TB infection.

Materials and Methods

Overview

Three distinct studies were undertaken sequentially. Studies involving human subjects or samples were conducted in accordance with principles expressed in the Declaration of Helsinki. Non-human primate studies were conducted in accordance with the United States Animal Welfare Act and the Guide for the Care and Use of Laboratory Animals of the Institute for Laboratory Animal Research, National Academies of Science. Each study was approved by the appropriate Institutional Review Boards as described.

(1) IFN-γ responses to TB antigens in Northern Californians with and without H. pylori infection.

The Stanford Infection and Family Transmission [SIFT] study was established in 1999 to evaluate incidence of H. pylori infection within predominately immigrant communities of the South Peninsula, San Francisco Bay. Since 2003, we have tested concurrently for latent M. tuberculosis infection. Data used in this report include 339 healthy residents of Santa Clara County, CA who gave written consent between September 2003 and May 2006 to provide blood for QuantiFERON-TB GOLD (in-tube) IFN-γ release assay (Cellestis, Ltd, Melbourne, Australia), as well as for H. pylori and other infectious disease testing, at the time of routine tuberculin skin test (Table 1). Children under 2 years of age, and individuals with history or symptoms of active tuberculosis were not recruited. The population is predominately Hispanic, including 50% born in a TB endemic country (90% Latin America). The study was approved by the Institutional Review Boards of Stanford University and the Santa Clara Valley Medical Center.

[Figure omitted. See PDF.]

Table 1. Population characteristics: Northern California H. pylori/LTBI studies.

https://doi.org/10.1371/journal.pone.0008804.t001

(2) H. pylori sero-prevalence in human tuberculosis case-contact cohorts.

De-identified plasma samples obtained at a baseline screening visit were recruited from the specimen banks of tuberculosis case-contact studies conducted by the Medical Research Council, The Gambia, West Africa [16] and the Aga Khan University, Karachi, Pakistan [14], respectively. Each study enrolled households based on an index case of active tuberculosis, and assessed participants clinically for at least 24 months from baseline, with overall rates of activation 1.1% (The Gambia [13]) and 6.4% (Karachi [14]) previously reported. Active TB was ascertained by symptoms, chest X-ray and AFB smear and culture in The Gambia [16], and by symptoms, chest X-ray and AFB smear in Pakistan [14]. Baseline TB infection was determined by positive (≥10 mm) TST and/or ELISPOT in The Gambia [17] and by positive TST (≥10 mm in Pakistan [14]. Blood samples recruited for the present studies were from HIV-negative subjects with blood drawn before the onset of treatment of a TB prevalent or incident case.

Sampling proportions and baseline characteristics of subjects whose samples were selected for analysis are shown in Table S4. From The Gambia, 549 samples were randomly selected in 2 phases from a pool of 2626 eligible samples (Figure 1A). The first group consisted of samples from 100/295 eligibleTB cases (household index cases) and 100/2271 eligible age- and sex-matched household contacts who were TB infected at baseline and known to have remained disease-free for at least 2 years of follow-up (nonprogressors). Samples from Gambian TB cases were proportionately representative of Gambian TB isolates (approximately 40% M. africanum and 60% M. tuberculosis [18]). The second sampling phase included samples from 29/32 subjects who developed active TB 3–47 months from baseline, and 320 age- and sex-matched nonprogressors. The study was approved by the Institutional Review Boards of Stanford University and the MRC Ethics Committee. A complete sample was obtained from the Pakistan cohort (Figure 1B), including 20 index TB cases, 8 incident TB cases ascertained 3–49 months from baseline, and 93 household contacts who remained disease-free. The study was approved by the Institutional Review Boards of Stanford University and the Aga Khan University Ethics Committee.

[Figure omitted. See PDF.]

Figure 1. Samples recruited for H. pylori testing from Tuberculosis Case-Contact Studies.

Blood samples were recruited for H. pylori serology testing from the specimen banks of tuberculosis case- contact studies carried out in (A) The Gambia, West Africa (Ref. 13,16), and (B) Karachi, Pakistan (Ref 14). Each study followed household members exposed to an active (index) case of tuberculosis for at least 2 years. Eligible samples were from HIV-negative participants. Samples from Gambia were randomly selected in 2 groups to match household contacts by age and sex to index and incident TB cases, respectively. LTBI: latent tuberculosis infection at baseline, defined as TST ≥10mm or ELISPOT ≥8 SFU (Gambia), or as TST ≥10mm (Pakistan). Baseline characteristics are shown in Table S4.

https://doi.org/10.1371/journal.pone.0008804.g001

(3) TB challenge in cynomolgus macaques with and without naturally acquired H. pylori infection.

Stored baseline sera, frozen gastric necropsy samples, and clinical necropsy reports were obtained from a convenience sample of 45 cynomolgus macaques (Macaca fasicularis) (>4 years of age) used in ongoing or completed low-dose TB challenge studies. All monkeys included in our study had been challenged endotracheally with 25 CFU of the Erdman strain of M. tuberculosis. Monkeys were assessed clinically for at least eight months post-challenge, and were classified as having active TB or latent infection based on previously defined criteria [19]. Specifically, monkeys were classified as having active TB if they had any clinical signs of disease, including weight loss, appetite loss, cough, radiographic findings, elevated erythrocyte sedimentation rate (ESR), or BAL or gastric aspirate that grew M. tuberculosis after the first two months of infection. Monkeys were classified as latent if they exhibited no signs of active disease (by the measures described above) and had culture negative BAL and gastric aspirate samples after 2 months of infection. These criteria have been validated at necropsy in a large group of monkeys [20]. The Pittsburgh model has previously yielded approximately 50% active and 50% latent disease post-challenge [19], [20]. The outcome is independent of gender, weight or age (between 4–10 years of age) in this model [20]. The animals were housed and maintained in accordance with standards established in the Animal Welfare Act and the Guide for the Care and Use of Laboratory Animals. All procedures and protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Pittsburgh.

Laboratory Methods

H. pylori infection in humans.

The diagnosis of H. pylori infection was ascertained by enzyme-linked immunosorbent assay (ELISA). Per protocol, all samples were run in triplicate by technicians blinded to the TB infection or outcome classification of samples, and samples with different infection classifications were intermixed on the same plates and run on the same days. Final serologic interpretations were completed before samples were linked to case records.

For the Northern California subjects, a high molecular weight whole cell lysate ELISA antigen was derived from 2 Asian, 2 Mexican, and 2 US isolates of H. pylori with results interpreted according to validated cut-offs, as previously described [2], [21]. Because antibodies to H. pylori's immunodominant CagA protein, present in approximately 65% of H. pylori isolates, may be more reliable in samples from developing countries [22], [23], Pakistan and Gambian samples were tested for IgG antibody response to the orv220 fragment of H. pylori CagA (courtesy H. Kleanthous) as previously described [24]. A sample was considered positive if optical density reading exceeded the mean + 3SD of 15 CagA negative controls. Indeterminate samples (n = 24) were classified as negative for analysis.

Measles antibodies.

To establish baseline humoral response, quantitative IgG antibody response to measles was compared in a subset of samples from 100 culture-confirmed Gambian TB patients and 100 age and sex-matched household contacts with latent infection, using the Bioquant IgG ELISA (San Diego, CA) with qualitative results interpreted according to manufacturer's criteria.

TB antigen-induced cytokine studies.

We used the QuantiFERON-TB-GOLD® (Cellestis, Ltd, Carnegie, Victoria, Aus) assay to quantify stimulated PBMC IFN-γ responses to specific M. tuberculosis peptides as previously described [25]. Quantitative results, expressed as IU/ml, representing the difference in IFN-γ response to M. tuberculosis peptides or PHA and a saline control for each subject, were transformed for statistical analysis using the natural log base. Residual supernatants from stimulated PBMCs were stored at −80°C and subsequently, 65 samples from adults were further assayed in a Luminex xMAP 200 platform using customized bead preparations (Beadlyte Human 26-plex Multi-Cytokine, Millipore, Billerica, MA). Concentrations for a standard reference curve were included on each plate per manufacturer's instructions. For each subject cytokine concentrations in the unstimulated control well were subtracted from TB specific responses, expressed as pg/ml.

H. pylori diagnostic procedures in monkeys.

Frozen serum samples obtained before M. tuberculosis challenge (N = 44) or soon thereafter (1 sample obtained 33 days post infection) were sent to Stanford University for ELISA. A rhesus-derived H. pylori strain was employed for the ELISA antigen. In prior studies with the rhesus model, this assay had an estimated sensitivity and specificity against endoscopy or breath test of 96% and 88% respectively [26]. Gastric tissue obtained at necropsy (n = 28 monkeys) and frozen at −80C for between 1 week and 22 months (median 13.8 months), was shipped to U.C. Davis, fixed, and processed in the laboratory of J. Solnick for H. pylori culture and histopathology respectively as previously described [15].

Statistical Analysis

Statistical analysis was conducted using SAS v. 9.3. All statistical tests were carried out at alpha set to 0.05 for a two-sided test. The following analyses were conducted:

(1) IFN-γ responses to TB antigens in Northern Californians with and without H. pylori infection.

To evaluate whether concurrent H. pylori infection affects the immune response to M. tuberculosis antigens, we compared quantitative TB specific IFN-γ responses stratified by H. pylori- and latent M. tuberculosis infection. H. pylori infection was defined by results of the whole cell lysate ELISA. We defined latent TB infection (LTBI) presumptively as either M. tuberculosis specific IFN-γ response ≥0.35 IU/ml or TST result ≥10 mm, with no signs or symptoms of active TB. A Generalized Linear Model was used to compare group means accounting for the interaction of H. pylori and LTBI as well as to adjust for potential confounders (age, sex, and country of origin); p-values are based on the F-test (Fisher's LSD) for pre-planned contrasts (e.g. H. pylori effect within LTBI). For multiplex-cytokine analysis, Principal Components Analysis [27] was performed with the correlation matrix composed of six variables found to discriminate by Wilcoxon's test between 40 latently infected and 25 controls (Tables S1 and S2), and components having Eigenvalue >1 were selected to compute summary component scores for each subject using eigenvector coefficients.

Comparison of H. pylori prevalence in human tuberculosis case-contact cohorts.

We compared rates of H. pylori CagA infection in index TB cases, incident TB cases, and household contacts known not to have progressed to active disease during follow-up (nonprogressors). Logistic regression was used to evaluate factors associated with H. pylori infection in each cohort and in the cohorts combined. Odds ratios and 95% confidence intervals of H. pylori infection in nonprogressors compared to prevalent or incident TB cases were computed with adjustment for age, gender, latent M. tuberculosis infection at baseline, and cohort location (Pakistan or The Gambia). Goodness of fit was evaluated using the Hosmer-Lemeshow test [28]. A generalized nonlinear mixed model with random intercept (SAS GLIMMIX) was used to examine results with adjustment for household membership.

M. tuberculosis challenge in cynomolgus macaques with and without naturally acquired H. pylori infection.

Monkeys were categorized clinically by 6–8 months after aerosol infection as having active tuberculosis or latent infection. H. pylori infection in monkeys was defined as a positive serologic test for H. pylori prior to M. tuberculosis infection. Because gastric tissue had not been obtained or conserved for the purposes of H. pylori histology or culture, negative results to these two tests were not considered reliable for determining presence or absence of infection. Relative risk and 95% confidence intervals of active vs. latent tuberculosis in H. pylori infected versus uninfected monkeys was computed.

Results

IFN-γ Responses to TB Antigens in Northern Californians with Concurrent H. pylori Infection

Of 339 subjects (113 children and 226 adults), 97 (29%) individuals met criteria for latent TB infection, including 82 (24%) individuals with TST induration ≥10mm and 48 individuals (14%) with TB specific antigen induced IFN-γ ≥0.35 IU/ml. A total 242 (71%) individuals were negative by both criteria and classified as not latently infected. Of subjects classified as latently infected, 45 (46%) were H. pylori seropositive as compared with 52 (22%) of the 242 subjects classified as LTBI negative (p<0.001).

Compared to 52 latently infected subjects without H. pylori infection, mean IFN-γ responses to specific TB antigens were approximately 1.5 fold greater in 46 subjects with concurrent H. pylori infection (Figure 2A), and this difference remained significant after adjusting for age, sex and country of birth (p = 0.04, ANOVA). In contrast, IFN-γ responses did not vary significantly with respect to H. pylori infection among 242 LTBI-negatives (p =  0.40), indicating an interaction effect between H. pylori and LTBI (p = 0.03, ANOVA). These results were similar when restricting the definition of LTBI to TST positivity only (data not shown).

[Figure omitted. See PDF.]

Figure 2. IFN-γ responses to TB antigens are amplified in concurrently infected subjects.

A: TB antigen induced (24 hour) IFN-γ responses in 97 subjects classified as TB infected [LTBI] and 242 subjects classified as without LTBI, stratified by H. pylori infection status; p-values denote age and sex-adjusted difference within LTBI classification (ANOVA). B. panel A obtained by substituting results of Hepatitis A virus total IgG antibody response [HAV] for H. pylori response; C. mean IFN-γ levels within 97 LTBI+ by H. pylori and HAV antibody test results; p-values denote contrast within each infection grouping. LTBI+: TST≥10 mm induration or QuantiFERON-TB GOLD® positive (≥0.35 IU/ml difference over unstimulated well); LTBI−: TST<10mm and QuantiFERON-TB GOLD®-<0.35 IU/ml; error bars represent 95% confidence interval of the least squares means.

https://doi.org/10.1371/journal.pone.0008804.g002

The effect on IFN-γ responses to M. tuberculosis antigens of past exposure to Hepatitis A virus, a picornavirus infection with epidemiologic patterns similar to those of H. pylori [29] was similar to that for H. pylori (Figure 2B). In fact, in a 3-way interaction model, having H. pylori infection, HAV and LTBI was associated with greater IFN-γ responses to TB than having either infection singly with LTBI (Figure 2C).

In the 65 adults (40 with LTBI and 25 without) tested by 26-multiplex cytokine assay (Table S1), IL2, TNF-α, CXCL-10 (IP10), IL-13 and IL-5, as well as IFN-γ, were differentially detected in latently infected vs. uninfected subjects (Table S2). Within the 40 latently infected, samples from the 23 subjects with concurrent H. pylori infection had higher summary measures of Th-1-type (IFN-γ, IL2, TNF-α, CXCL-10) cytokine responses to TB antigens (p = 0.03, Wilcoxon) than did the 17 H. pylori seronegative (Figure 3a and b; Table S3). Overall, 9 (82%) of 11 subjects classified as having dominant Th1-type cytokine responses to M. tuberculosis infection were H. pylori seropositive (p = 0.05 Fishers exact test).

[Figure omitted. See PDF.]

Figure 3. Concurrent H. pylori infection is associated with Th1+/Th2− type profile.

A. Scatterplot of principal component scores for 40 adults with latent TB infection (either QuantiFERON-TB GOLD® or TST positive) obtained after linear transformation with eigenvector coefficients. Vertical-axis: 1st component (eigenvalue 2.6), which is largely explained by IFN-γ and IL-2, and to a lesser extent IP-10 and TNF-α. Horizontal axis: 2nd PC (eigenvalue 1.5), characterized by loading of IL-13 and IL-5 and negative correlations with the four inflammatory markers. Red circles: 23 H. pylori infected; Black circles: 17 H. pylori seronegative. Reference lines denote quadrants centered on 0; B. comparison of median composite Th1 and Th2 component scores; p-values computed by Wilcoxon's 2-sided median test.

https://doi.org/10.1371/journal.pone.0008804.g003

Comparison of H. pylori Sero-Prevalence in Human Tuberculosis Case-Contact Cohorts

Among a total 670 samples tested, 425 (63%) were H. pylori seropositive according to the CagA assay, including 59/121 (49%) of Karachi, Pakistan and 366/549 (67%) of Gambian household contacts (p = 0.0002, supplemental Table S5). H. pylori seroprevalence varied significantly by TB outcome classification (Table 2, and Table S6 for results by cohort). Compared to 513 household contacts who remained disease-free throughout follow-up, the 120 TB cases were about ½ as likely to be H. pylori CagA positive (AOR: 0.55 (95% CI 0.36–0.83, p = 0.005), while seroprevalence was not different between nonprogressors and 37 incident TB cases (AOR: 1.35 [95% CI 0.65–3.0), p = 0.44). These results were similar when restricted to samples from 466 subjects considered latently infected, as well as when accounting for household membership in a random intercept nonlinear mixed model.

[Figure omitted. See PDF.]

Table 2. Factors associated with H. pylori CagA infection in tuberculosis case-contact cohort samples (adjusted odds ratio).

https://doi.org/10.1371/journal.pone.0008804.t002

To explore whether the diminished antibody responses to H. pylori in prevalent TB patients might result from immune deficits associated with having active disease, we evaluated measles antibody responses in 100 Gambian culture-confirmed TB cases and 100 age- and sex-matched latently infected nonprogressors. Equal numbers of cases and contacts responded to a measles IgG antibody test (90% and 88% respectively) with virtually identical mean optical density values (Figure S1), suggesting that active TB disease did not cause a diminution of humoral responses.

TB Challenge in Cynomolgus Macaques with and without Naturally Acquired H. pylori Infection

Of the 45 monkeys, 4 monkeys had indeterminate H. pylori results by the rhesus-based H. pylori ELISA and were excluded from the analysis. Among the remaining 41 monkeys, 30 (73.2%) were seropositive and 11 (26.8%) were seronegative for H. pylori. Although, as expected, culture yields in seropositive monkeys were low due to tissue autolysis and storage, all 6 H. pylori culture-positive monkeys were positive by serology, as were 4 of 6 H. pylori histology positive monkeys. Of the 30 monkeys with positive H. pylori serology (Table 3), only 5 (16.7%) developed active tuberculosis whereas 6 (54.6%) of the 11 negative monkeys developed active tuberculosis (relative risk 0.31, 95% CI 0.12–0.80, p = 0.04, Fisher's Exact test).

[Figure omitted. See PDF.]

Table 3. Seroprevalence of H. pylori infection in 41 Pittsburgh cynomolgus macaques by outcome of TB challenge at 6–8 months.

https://doi.org/10.1371/journal.pone.0008804.t003

Discussion

Humans are colonized by complex, site-specific microbial communities that are increasingly implicated in human health and disease in unexpected ways. In some cases, microbial communities are thought to modulate non-infectious diseases, such as obesity [30], asthma and autoimmune diseases [31]. Viewed broadly, the human microbiota may be a major regulator of the immune system modulating not only inflammatory disorders (the “hygiene hypothesis”), but responses to infectious challenges as well [32]. Because they continuously stimulate non-specific responses in the host, chronic mucosal infections may be particularly important in this regard.

The high prevalence of H. pylori in populations where TB and other lethal infections remain endemic suggests the host-pathogen interplay of these infections has co-evolved. In this report, we have presented evidence from three different study designs that H. pylori infection affects response to M. tuberculosis. First, we found in a cross-sectional human study that H. pylori is associated with enhanced IFN-γ and Th1-like responses to specific TB antigens. Second, in baseline samples from two high risk human tuberculosis case-contact cohorts, we observed that infected household contacts who maintain latency over two years are significantly more likely to have concurrent H. pylori infection than are TB cases, although seroprevalence was not different in incident TB cases. Finally, in a retrospective cohort study of low-dose M. tuberculosis challenge monkeys, we observed that H. pylori-infected animals are significantly less likely to develop active disease than are uninfected animals. While further studies are indicated, taken together, these lines of investigation offer a heretofore unexplored role for infections like H. pylori to alter the outcome of M. tuberculosis infection.

We propose two potential models by which H. pylori could promote a protective immune response to TB infection. In the first model, an infection in early childhood could permanently differentiate immature T-cells to a Th1-like phenotype. Such a “hygiene hypothesis,” has been advanced for hepatitis A [33], and would favor past as well as ongoing infections contributing to a state of heightened immunity. Alternatively, H. pylori might induce a bystander effect with continuous inflammation and T-cell signaling enhancing the host's innate response to a spectrum of infectious challenges. Similar effects have been demonstrated with γ-herpesvirus in mice challenged with Listeria monocytogenes and Yersinia pestis [34]. These authors speculate that non- specific induction of interferon-γ (IFN-γ) activates macrophages and primes innate defenses to other infections. We did not test for antibodies to HAV or herpesviridae in the human tuberculosis case-contact cohorts. Because these exposures are likely to be very common in populations where both H. pylori and M. tuberculosis infections are common, more systematic sampling designs may be needed to adequately explore interaction effects.

H. pylori naturally infects macaques. The fact that we were able to replicate a significant association of H. pylori infection with latent outcomes in the Pittsburgh cynomolgus monkey TB challenge model [19], [35] offers new opportunities to explore mechanistic arguments in depth. Because the present work is based on a convenience sample from the Pittsburgh laboratory, repeated measures of immunologic responses and clinical progression were not investigated. More systematic experimental study designs, including prospective studies utilizing H. pylori challenge, are planned.

The accuracy of H. pylori serology in the developing world is suboptimal [22]. Although the CagA assay may be more reliable for comparing different populations, misclassification of H. pylori infection status still cannot be excluded. Typically, misclassification tends to yield a null result unless, for some reason, cases and controls respond differently to the assay. We speculated that TB cases might have weakened antibody responses, causing us to have a spurious result. However, the fact that measles antibody titers were robust and virtually the same in Gambian TB cases and age and sex-matched latently infected contacts argues against this explanation of results. That H. pylori seroprevalence did not differ between incident TB cases and nonprogressors in our cohort samples, while limiting our conclusions, can also reflect artifacts of the TBCC study model, including the low numbers of secondary cases, ascertainment differences or biases, as well as limitations of H. pylori serologic detection in this setting. In both cohorts, most cases of TB were identified at an initial screening visit, and M. tuberculosis infection at baseline was a relatively weak predictor of progression [14], [36]. Thus, continued work with longitudinal cohorts may benefit from multi-site study designs incorporating additional H. pylori diagnostics as well as other prognostic biomarkers of immune response to TB exposure and infection.

M. tuberculosis specific antigen interferon-γ release assays are important noninvasive tools for measuring immunogenicity of the heterologous prime boost T-cell based vaccines for TB [37], [38]. Our results raise the possibility that H. pylori infection and other Th-1 modifying infections present in the host background can alter these profiles. As our results also do not exclude the possibility that M. tuberculosis modifies the host response to H. pylori infection, PBMC responses to TB antigens pre- and post- antibiotic treatment for H. pylori would help shed light on the specificity of our findings, including reversibility. In vitro studies examining possible mechanisms of T-cell cross reactivity, such as effect of H. pylori antigen on M. tuberculosis antigen presenting cells and MHC expression, are also needed.

Why only 10% of infected individuals succumb to tuberculosis remains one of the most vexing public health questions–one which the one-pathogen-one-disease paradigm is ill-equipped to answer. While preliminary, our work suggests that one factor contributing to the clinical outcome of TB infection may be a concurrent chronic infection. The hypothesis that the human microbiome has evolved to provide context-specific competitive risk advantages to the host [39] also raises the intriguing possibility that our microbiota can be manipulated to modulate disease risk from M. tuberculosis, as well as other common human pathogens [40].

Supporting Information

[Figure omitted. See PDF.]

Table S1.

Characteristics of samples selected for multiple cytokine panels (Northern California study). 1,2LTBI: latent tuberculosis infection; +, QuantiFERON [QFT]-TB GOLD® or tuberculin skin test (≥10mm) positive; −, QuantiFERON-TB GOLD® negative and tuberculin skin test negative (<10 mm induration). *** p<0.01, ** 0.01≤p<0.05, *0.05≤p<0.10 vs. unselected. p-values calculated by Chi square or Fisher's exact test.

https://doi.org/10.1371/journal.pone.0008804.s001

(0.04 MB DOC)

Table S2.

Whole blood TB antigen induced cytokine concentrations (pg/ml) in 65/225 adults. LTBI: latent tuberculosis infection; +, QuantiFERON-TB GOLD® or tuberculin skin test (≥10mm) positive; −, QuantiFERON-TB GOLD® negative and tuberculin skin test negative (<10 mm induration). IQR, interquartile range. % responding, based on proportion of difference values below or above extrapolation limits of a 5 parameter logistic curve for each analyte.

https://doi.org/10.1371/journal.pone.0008804.s002

(0.04 MB DOC)

Table S3.

Results of principal components analysis performed with six variables (TB antigen-induced cytokine/chemokine results selected to discriminate between latently infected adults and negative controls). Components with Eigenvalues >1 are shown.

https://doi.org/10.1371/journal.pone.0008804.s003

(0.04 MB DOC)

Table S4.

Baseline characteristics of human cohort samples. LTBI: latent tuberculosis infection determined by TST ≥10mm and/or ELISPOT ≥8 SFU (Gambia) or TST ≥10 mm (Pakistan).

https://doi.org/10.1371/journal.pone.0008804.s004

(0.04 MB DOC)

Table S5.

Seroprevalence of H. pylori CagA infection in TB cases and household contacts: differences between The Gambia and Pakistan.

https://doi.org/10.1371/journal.pone.0008804.s005

(0.03 MB DOC)

Table S6.

Factors associated with H. pylori CagA infection in Gambia and Pakistan tuberculosis case-contact cohort samples (univariate analysis).

https://doi.org/10.1371/journal.pone.0008804.s006

(0.04 MB DOC)

Figure S1.

Measles antibody responses in 100 Gambian TB cases and 100 latently infected household contacts. Ref. line: positive cut-off (Bioquant IgG ELISA, San Diego, CA); Nonprogressor, household contact of TB index case remaining disease-free for at least 2 years from baseline; TB infected, positive TST ≥10mm or ELISPOT ≥8 SFU at baseline.

https://doi.org/10.1371/journal.pone.0008804.s007

(0.04 MB DOC)

Acknowledgments

The authors gratefully acknowledge the assistance of the Santa Clara County, CA Public Health Department Immunization Clinic with recruitment for the Northern California series, members of the Gambian TB case-contact research team, Dr. G. Dawood and Firdaus Shaid of the Karachi research team, the Pakistan National Commission of Science and Technology, and the Pakistan Higher Education Commission for supporting work with the Karachi cohort. We are grateful to Carolyn Bigbee (University of Pittsburgh) for excellent technical assistance, Dr. Edwin Klein for clinical expertise and necropsy, and the veterinary technical and husbandry staff at the University of Pittsburgh. We also wish to thank Alicia Chang (Stanford School of Medicine) for critical review of the manuscript, Thomas D. Haggerty (Stanford School of Medicine) for assistance with specimen analysis, and Maryam Liaqat (Stanford School of Medicine) for proofing the manuscript.

Author Contributions

Conceived and designed the experiments: SP JP. Performed the experiments: JS SY LMH NT DRC. Analyzed the data: SP. Contributed reagents/materials/analysis tools: BCD JS PLl RH RAA JLF. Wrote the paper: SP. Gambian study sample recruitment: BCdJ RAA. Performed primate study experiments: JS LMH DRC. Contributed to primate study presentation: JS JLF. Northern California recruitment: MdlLS. Performed human and primate study experiments: SY. Primate study sample recruitment: PLL JLF. Performed Karachi study experiments: NT. Contributed to Gambian study presentation: PCH. Karachi study recruitment: RH.

Citation: Perry S, de Jong BC, Solnick JV, Sanchez MdlL, Yang S, Lin PL, et al. (2010) Infection with Helicobacter pylori Is Associated with Protection against Tuberculosis. PLoS ONE5(1): e8804. https://doi.org/10.1371/journal.pone.0008804

References

1. Linz B, Balloux F, Moodley Y, Manica A, Liu H, et al. (2007) An African origin for the intimate association between humans and Helicobacter pylori. Nature 445: 915–918.B. LinzF. BallouxY. MoodleyA. ManicaH. Liu2007An African origin for the intimate association between humans and Helicobacter pylori.Nature445915918

2. Perry S, Sanchez L, Yang S, Haggerty TD, Hurst P, et al. (2004) Helicobacter pylori and risk of gastroenteritis. J Infect Dis 190: 303–310.S. PerryL. SanchezS. YangTD HaggertyP. Hurst2004Helicobacter pylori and risk of gastroenteritis.J Infect Dis190303310

3. Blaser MJ, Chen Y, Reibman J (2008) Does Helicobacter pylori protect against asthma and allergy? Gut 57: 561–567.MJ BlaserY. ChenJ. Reibman2008Does Helicobacter pylori protect against asthma and allergy?Gut57561567

4. World Health Organization (2008) Global TB Control: Surveillance, Planning, Financing. Geneva. World Health Organization2008Global TB Control: Surveillance, Planning, Financing.Geneva

5. Flynn JL, Chan J (2001) Immunology of tuberculosis. Annu Rev Immunol 19: 93–129.JL FlynnJ. Chan2001Immunology of tuberculosis.Annu Rev Immunol1993129

6. Saunders BM, Britton WJ (2007) Life and death in the granuloma: immunopathology of tuberculosis. Immunol Cell Biol 85: 103–111.BM SaundersWJ Britton2007Life and death in the granuloma: immunopathology of tuberculosis.Immunol Cell Biol85103111

7. Kaufmann SH (2001) How can immunology contribute to the control of tuberculosis? Nat Rev Immunol 1: 20–30.SH Kaufmann2001How can immunology contribute to the control of tuberculosis?Nat Rev Immunol12030

8. Kaufmann SH, McMichael AJ (2005) Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat Med 11: S33–44.SH KaufmannAJ McMichael2005Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis.Nat Med11S3344

9. Winthrop KL (2006) Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2: 602–610.KL Winthrop2006Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor.Nat Clin Pract Rheumatol2602610

10. Mitchell HM, Li YY, Hu PJ, Liu Q, Chen M, et al. (1992) Epidemiology of Helicobacter pylori in southern China: identification of early childhood as the critical period for acquisition. J Infect Dis 166: 149–153.HM MitchellYY LiPJ HuQ. LiuM. Chen1992Epidemiology of Helicobacter pylori in southern China: identification of early childhood as the critical period for acquisition.J Infect Dis166149153

11. Torres MA, Passaro DJ, Watanabe J, Parsonnet J, Small P, et al. (2003) No association between Helicobacter pylori and Mycobacterium tuberculosis infections among gastrointestinal clinic attendees in Lima, Peru. Epidemiol Infect 130: 87–91.MA TorresDJ PassaroJ. WatanabeJ. ParsonnetP. Small2003No association between Helicobacter pylori and Mycobacterium tuberculosis infections among gastrointestinal clinic attendees in Lima, Peru.Epidemiol Infect1308791

12. Roussos A, Philippou N, Mantzaris GJ, Gourgoulianis KI (2006) Respiratory diseases and Helicobacter pylori infection: is there a link? Respiration 73: 708–714.A. RoussosN. PhilippouGJ MantzarisKI Gourgoulianis2006Respiratory diseases and Helicobacter pylori infection: is there a link?Respiration73708714

13. Hill PC, Jackson-Sillah DJ, Fox A, Brookes RH, de Jong BC, et al. (2008) Incidence of Tuberculosis and the Predictive Value of ELISPOT and Mantoux Tests in Gambian Case Contacts. PLoS ONE 3: e1379.PC HillDJ Jackson-SillahA. FoxRH BrookesBC de Jong2008Incidence of Tuberculosis and the Predictive Value of ELISPOT and Mantoux Tests in Gambian Case Contacts.PLoS ONE3e1379

14. Hussain R, Talat N, Shahid F, Dawood G (2007) Longitudinal tracking of cytokines after acute exposure to tuberculosis: association of distinct cytokine patterns with protection and disease development. Clin Vaccine Immunol 14: 1578–1586.R. HussainN. TalatF. ShahidG. Dawood2007Longitudinal tracking of cytokines after acute exposure to tuberculosis: association of distinct cytokine patterns with protection and disease development.Clin Vaccine Immunol1415781586

15. Solnick JV, Chang K, Canfield DR, Parsonnet J (2003) Natural acquisition of Helicobacter pylori infection in newborn rhesus macaques. J Clin Microbiol 41: 5511–5516.JV SolnickK. ChangDR CanfieldJ. Parsonnet2003Natural acquisition of Helicobacter pylori infection in newborn rhesus macaques.J Clin Microbiol4155115516

16. Jackson-Sillah D, Hill PC, Fox A, Brookes RH, Donkor SA, et al. (2007) Screening for tuberculosis among 2381 household contacts of sputum-smear-positive cases in The Gambia. Trans R Soc Trop Med Hyg 101: 594–601.D. Jackson-SillahPC HillA. FoxRH BrookesSA Donkor2007Screening for tuberculosis among 2381 household contacts of sputum-smear-positive cases in The Gambia.Trans R Soc Trop Med Hyg101594601

17. Jeffries DJ, Hill PC, Fox A, Lugos M, Jackson-Sillah DJ, et al. (2006) Identifying ELISPOT and skin test cut-offs for diagnosis of Mycobacterium tuberculosis infection in The Gambia. Int J Tuberc Lung Dis 10: 192–198.DJ JeffriesPC HillA. FoxM. LugosDJ Jackson-Sillah2006Identifying ELISPOT and skin test cut-offs for diagnosis of Mycobacterium tuberculosis infection in The Gambia.Int J Tuberc Lung Dis10192198

18. de Jong BC, Hill PC, Aiken A, Awine T, Antonio M, et al. (2008) Progression to active tuberculosis, but not transmission, varies by Mycobacterium tuberculosis lineage in The Gambia. J Infect Dis 198: 1037–1043.BC de JongPC HillA. AikenT. AwineM. Antonio2008Progression to active tuberculosis, but not transmission, varies by Mycobacterium tuberculosis lineage in The Gambia.J Infect Dis19810371043

19. Capuano SV 3rd, Croix DA, Pawar S, Zinovik A, Myers A, et al. (2003) Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect Immun 71: 5831–5844.SV Capuano 3rdDA CroixS. PawarA. ZinovikA. Myers2003Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection.Infect Immun7158315844

20. Lin PL, Rodgers M, Smith L, Bigbee M, Myers A, et al. (2009) Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect Immun. PL LinM. RodgersL. SmithM. BigbeeA. Myers2009Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model.Infect Immun

21. Replogle ML, Glaser SL, Hiatt RA, Parsonnet J (1995) Biologic sex as a risk factor for Helicobacter pylori infection in healthy young adults. Am J Epidemiol 142: 856–863.ML ReplogleSL GlaserRA HiattJ. Parsonnet1995Biologic sex as a risk factor for Helicobacter pylori infection in healthy young adults.Am J Epidemiol142856863

22. Romero-Gallo J, Perez-Perez GI, Novick RP, Kamath P, Norbu T, et al. (2002) Responses of endoscopy patients in Ladakh, India, to Helicobacter pylori whole-cell and Cag A antigens. Clin Diagn Lab Immunol 9: 1313–1317.J. Romero-GalloGI Perez-PerezRP NovickP. KamathT. Norbu2002Responses of endoscopy patients in Ladakh, India, to Helicobacter pylori whole-cell and Cag A antigens.Clin Diagn Lab Immunol913131317

23. Perez-Perez GI, Bhat N, Gaensbauer J, Fraser A, Taylor DN, et al. (1997) Country-specific constancy by age in cagA+ proportion of Helicobacter pylori infections. Int J Cancer 72: 453–456.GI Perez-PerezN. BhatJ. GaensbauerA. FraserDN Taylor1997Country-specific constancy by age in cagA+ proportion of Helicobacter pylori infections.Int J Cancer72453456

24. Parsonnet J, Replogle M, Yang S, Hiatt R (1997) Seroprevalence of CagA-positive strains among Helicobacter pylori-infected, healthy young adults. J Infect Dis 175: 1240–1242.J. ParsonnetM. ReplogleS. YangR. Hiatt1997Seroprevalence of CagA-positive strains among Helicobacter pylori-infected, healthy young adults.J Infect Dis17512401242

25. Perry S, Sanchez L, Yang S, Agarwal Z, Hurst P, et al. (2008) Reproducibility of QuantiFERON-TB gold in-tube assay. Clin Vaccine Immunol 15: 425–432.S. PerryL. SanchezS. YangZ. AgarwalP. Hurst2008Reproducibility of QuantiFERON-TB gold in-tube assay.Clin Vaccine Immunol15425432

26. Solnick JV, Canfield DR, Yang S, Parsonnet J (1999) Rhesus monkey (Macaca mulatta) model of Helicobacter pylori: noninvasive detection and derivation of specific-pathogen-free monkeys. Lab Anim Sci 49: 197–201.JV SolnickDR CanfieldS. YangJ. Parsonnet1999Rhesus monkey (Macaca mulatta) model of Helicobacter pylori: noninvasive detection and derivation of specific-pathogen-free monkeys.Lab Anim Sci49197201

27. Affifi AA, Clark V (1990) Principal Components Analysis. Computer Aided Multivariate Analysis. New York: Chapman & Hall. pp. 371–393.AA AffifiV. Clark1990Principal Components Analysis. Computer Aided Multivariate AnalysisNew YorkChapman & Hall371393

28. Hosmer DW, Lemeshow S (1989) Applied Logistic Regression. New York, NY: Wiley & Sons. DW HosmerS. Lemeshow1989Applied Logistic RegressionNew York, NYWiley & Sons

29. Matricardi PM, Rosmini F, Riondino S, Fortini M, Ferrigno L, et al. (2000) Exposure to foodborne and orofecal microbes versus airborne viruses in relation to atopy and allergic asthma: epidemiological study. Bmj 320: 412–417.PM MatricardiF. RosminiS. RiondinoM. FortiniL. Ferrigno2000Exposure to foodborne and orofecal microbes versus airborne viruses in relation to atopy and allergic asthma: epidemiological study.Bmj320412417

30. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, et al. (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444: 1027–1031.PJ TurnbaughRE LeyMA MahowaldV. MagriniER Mardis2006An obesity-associated gut microbiome with increased capacity for energy harvest.Nature44410271031

31. Wills-Karp M, Santeliz J, Karp CL (2001) The germless theory of allergic disease: revisiting the hygiene hypothesis. Nat Rev Immunol 1: 69–75.M. Wills-KarpJ. SantelizCL Karp2001The germless theory of allergic disease: revisiting the hygiene hypothesis.Nat Rev Immunol16975

32. Noverr MC, Huffnagle GB (2004) Does the microbiota regulate immune responses outside the gut? Trends Microbiol 12: 562–568.MC NoverrGB Huffnagle2004Does the microbiota regulate immune responses outside the gut?Trends Microbiol12562568

33. McIntire JJ, Umetsu DT, DeKruyff RH (2004) TIM-1, a novel allergy and asthma susceptibility gene. Springer Semin Immunopathol 25: 335–348.JJ McIntireDT UmetsuRH DeKruyff2004TIM-1, a novel allergy and asthma susceptibility gene.Springer Semin Immunopathol25335348

34. Barton ES, White DW, Cathelyn JS, Brett-McClellan KA, Engle M, et al. (2007) Herpesvirus latency confers symbiotic protection from bacterial infection. Nature 447: 326–329.ES BartonDW WhiteJS CathelynKA Brett-McClellanM. Engle2007Herpesvirus latency confers symbiotic protection from bacterial infection.Nature447326329

35. Lin PL, Pawar S, Myers A, Pegu A, Fuhrman C, et al. (2006) Early events in Mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun 74: 3790–3803.PL LinS. PawarA. MyersA. PeguC. Fuhrman2006Early events in Mycobacterium tuberculosis infection in cynomolgus macaques.Infect Immun7437903803

36. Hill PC, Brookes RH, Fox A, Jackson-Sillah D, Jeffries DJ, et al. (2007) Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection. PLoS Med 4: e192.PC HillRH BrookesA. FoxD. Jackson-SillahDJ Jeffries2007Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection.PLoS Med4e192

37. McShane H, Hill A (2005) Prime-boost immunisation strategies for tuberculosis. Microbes Infect 7: 962–967.H. McShaneA. Hill2005Prime-boost immunisation strategies for tuberculosis.Microbes Infect7962967

38. Hanekom WA, Dockrell HM, Ottenhoff TH, Doherty TM, Fletcher H, et al. (2008) Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Med 5: e145.WA HanekomHM DockrellTH OttenhoffTM DohertyH. Fletcher2008Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations.PLoS Med5e145

39. Dethlefsen L, McFall-Ngai M, Relman DA (2007) An ecological and evolutionary perspective on human-microbe mutualism and disease. Nature 449: 811–818.L. DethlefsenM. McFall-NgaiDA Relman2007An ecological and evolutionary perspective on human-microbe mutualism and disease.Nature449811818

40. Neutra MR, Kozlowski PA (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6: 148–158.MR NeutraPA Kozlowski2006Mucosal vaccines: the promise and the challenge.Nat Rev Immunol6148158